Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.54 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | GAA | P10253 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | GFER | P55789 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PLEC | Q15149 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559674 | 0.85 | PRKCI (0.53) | ACE2TDP1GRM1MEN1CYP1A2 | |
| SCHEMBL22897740 | 0.85 | PRKCI (0.53) | ACE2TDP1GRM1MEN1CYP1A2 | |
| SCHEMBL13903051 | 0.85 | ACE2 (0.51) | ACE2TDP1GRM1MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7965073 | 0.83 | ACE2 (0.50) | ACE2TDP1GRM1MEN1CYP1A2 | |
| SCHEMBL13816269 | 0.82 | ACE2 (0.61) | ACE2TDP1GRM1MEN1CYP1A2 | |
| SCHEMBL7398459 | 0.80 | GRM1 (0.68) | ACE2TDP1GRM1MEN1CYP1A2 | |
| SCHEMBL13958157 | 0.80 | KDM4E (0.62) | KDM4EGAAMAPTALDH1A1HPGD | |
| SCHEMBL8381715 | 0.80 | GRM1 (0.68) | ACE2TDP1GRM1MEN1CYP1A2 | |
| SCHEMBL6557670 | 0.80 | GRM1 (0.46) | ACE2TDP1GRM1MEN1CYP1A2 | |
| SCHEMBL18666525 | 0.80 | ALDH1A1 (0.52) | ACE2TDP1GRM1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953927-B1 | SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS | DRACONIS PHARMA S L (ES) | 2016-11-16 | — | — | EP | disclosed |
| US-20150376129-A1 | SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS | DRACONIS PHARMA, S.L. (ES) | 2015-12-31 | — | — | US | disclosed |
| EP-2953927-A1 | SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS | Draconis Pharma, S.L. (ES) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014122267-A1 | SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS | DRACONIS PHARMA, S.L. (ES) | 2014-08-14 | — | — | WO | disclosed |
| EP-2765128-A1 | Substituted benzamides with activity towards EP4 receptors | Almirall, S.A. (ES) | 2014-08-13 | — | — | EP | disclosed |
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-0685470-B1 | Benzene derivatives and pharmaceutical composition | KUREHA CHEMICAL IND CO LTD (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-5747541-A | Substituted benzoylguanidines, a process for their preparation, their use as medicament of diagnostic agent, and medicament comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-05 | — | — | US | disclosed |
| CN-1153773-A | substituted benzoyl guanidine its preparation, application as medicine or diagnostic reagent and medicine containing the said compound | HOECHST AG (DE) | 1997-07-09 | — | — | CN | disclosed |
| EP-0765868-A1 | Substituted bezoyl guanidines, process for their preparation, their use as antiarrhythmics or diagnostic agent as well as pharmaceuticals containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-02 | — | — | EP | disclosed |
| EP-0685470-A2 | Benzene derivatives and pharmaceutical composition | Kureha Chemical Industry Co., Ltd. (JP) | 1995-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376129-A1 | SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS | PTGER4, PTGER1, PTGER2 | ACE2 1376/4885TDP1 4719/4885GRM1 701/4885 |
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | NGF, BDNF, NTRK2 | ACE2 2009/4885TDP1 2055/4885GRM1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.